Neuro

Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial

Retrieved on: 
Donnerstag, Mai 9, 2024
Plus Therapeutics, Northwestern University, LM, PSTV, Hematology, Breast, Lung cancer, CNS, Incidence, Patient, Acquisition, MRI, Neuro, Central nervous system, Clinical trial, Plus, Associate, Therapy, Cancer, Medical imaging

AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, provided highlights from its investor call regarding the rationale for the acquisition of the leptomeningeal metastases diagnostic platform “CNSide” and topline data from the FORESEE clinical trial.

Key Points: 
  • Company acquired assets for the synergistic leptomeningeal metastases (LM) diagnostic platform, “CNSide™” and discussed potential partnering opportunities
    AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, provided highlights from its investor call regarding the rationale for the acquisition of the leptomeningeal metastases diagnostic platform “CNSide” and topline data from the FORESEE clinical trial.
  • “Leptomeningeal metastases (LM) is significantly underdiagnosed because current tests such as MRI and cytology lack sensitivity,” said Priya U. Kumthekar, M.D., Associate Professor of Neurology (Neuro-oncology) and Medicine (Hematology and Oncology) at Northwestern University & The Feinberg School of Medicine.
  • Plus discussed its plan to develop the CNSide diagnostic portfolio alongside its lead radiotherapeutic candidate rhenium (Re186) obisbemeda, and to seek partnering opportunities for CNSide.
  • Plus presented topline clinical trial data from the FORESEE trial which met its primary endpoint of clinical utility for the CNSide test in 40 patients with LM due to either breast or non-small cell lung cancer; a presentation of the full analysis is planned for the August 8-10 SNO/ASCO Meeting in Denver, CO.
    “Better diagnostics for leptomeningeal metastases are a clinical imperative for these patients and will help increase the market for our lead radiotherapeutic candidate rhenium (Re186) obisbemeda,” said Dr. Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer.

Brain Cancer Canada awards The Dwayne Andrews Glioblastoma Grant for Research to a study on the impact of anesthetics on brain cancer proliferation

Retrieved on: 
Mittwoch, Mai 8, 2024
Family, Research, SAC, Glioblastoma, Patient safety, Brain, Patient, Metastasis, Anesthetic, LHSC, Lawson Health Research Institute, London Health Sciences Centre, Neuro, Medical imaging

The grant will fund a study at London Health Sciences Centre (LHSC) titled “Comparison of intravenous and inhaled anesthetics on brain tumour proliferation: an in-vitro study”.

Key Points: 
  • The grant will fund a study at London Health Sciences Centre (LHSC) titled “Comparison of intravenous and inhaled anesthetics on brain tumour proliferation: an in-vitro study”.
  • The work aims to assess whether anesthetics used during glioblastoma brain tumour surgery can impact tumour growth, invasion, and metastasis.
  • This grant reflects our commitment to supporting innovative research that can lead to better outcomes for brain cancer patients," she said.
  • Our team thanks Brain Cancer Canada, the Andrews Family and Auto|One Group for helping us kickstart our work through the Dwayne Andrews GBM Research Grant.”
    The grant is the first in a series of four to be issued by Brain Cancer Canada during May, Brain Cancer Awareness Month.

Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis

Retrieved on: 
Mittwoch, Mai 8, 2024
Neuroprotection, Inflammation, Hospital, Safety, OCS, Diabetic retinopathy, Apoptosis, Optic neuritis, AON, IND, Disease, Patient, Paratriathlon, Geographic atrophy, Optic nerve, Neuron, Glaucoma, Ophthalmology, Neuro, Pharmaceutical industry

The Phase 2 ACUITY study is evaluating once-daily OCS-05 intravenous infusion in patients with AON.

Key Points: 
  • The Phase 2 ACUITY study is evaluating once-daily OCS-05 intravenous infusion in patients with AON.
  • OCS-05 has been granted orphan drug designation in both the United States and Europe, highlighting the importance of this unmet medical need.
  • In the meantime, we keep on working towards an IND submission for OCS-05 in the U.S. in 2024.
  • While corticosteroids are used to shorten the attack, there is no approved therapy for AON and unmet needs remain for therapies that can prevent vision loss after an acute episode of optic neuritis.

ClearPoint Neuro Reports First Quarter 2024 Results

Retrieved on: 
Dienstag, Mai 7, 2024
FDA, Brain, IDE, Software, Workflow, Prism, Interface (computing), Spine, Record, Paper, MRI, BLA, Marketing, Therapy, Telephone, SmartFrame, Growth, Neuro, Cryptocurrency

SOLANA BEACH, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2024.

Key Points: 
  • SOLANA BEACH, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2024.
  • “Our ClearPoint Neuro team enjoyed the best operating performance in our Company’s history, with contributions coming from all four of our growth pillars,” commented Joe Burnett, President and CEO at ClearPoint Neuro.
  • Financial Results – Quarter Ended March 31, 2024
    Total revenue was $7.6 million for the three months ended March 31, 2024, and $5.4 million for the three months ended March 31, 2023, which represents an increase of $2.2 million, or 41%.
  • Operating expenses for the first quarter of 2024 were $8.8 million, compared to $8.9 million for the first quarter of 2023.

Verasonics Announces New OEM Supply Model to Enhance Suite of Offerings Available to Commercial Customers

Retrieved on: 
Mittwoch, Mai 8, 2024
Medical Devices, Health, Health Technology, Other Science, Research, Science, Neuro, Breast imaging, High-intensity focused ultrasound, 3D printing

Verasonics, Inc., the leader in research ultrasound, announces a new OEM Supply Model to enhance corporate commercialization efforts for customers bringing ultrasound-based solutions to market.

Key Points: 
  • Verasonics, Inc., the leader in research ultrasound, announces a new OEM Supply Model to enhance corporate commercialization efforts for customers bringing ultrasound-based solutions to market.
  • Verasonics’ commercial suite of solutions now offers the Commercial Technology Licensing Model and the OEM Supply Model.
  • “By working with Verasonics and utilizing our innovative development platform, commercial licensees achieve substantial savings in development costs, and improved time to market.”
    Mr. Daigle added, “We are excited to add the OEM Supply Model to our suite of offerings available to commercial customers.
  • This program offers our customers additional flexibility and an alternate path for commercial supply.”
    For more information on Verasonics’ commercial suite of solutions, please contact [email protected] .

Biogennix Receives FDA Clearance for Expanded Use of Agilon Moldable and Morpheus Moldable Products

Retrieved on: 
Mittwoch, Mai 8, 2024
Medical Devices, Surgery, Medical Supplies, FDA, Biometrics, Other Health, Biotechnology, Alternative Medicine, General Health, Health, Collagen, News, Food, HCA, Surgeon, Spine, Porosity, Chemistry, Food and Drug Administration, Architecture, Neuro

Irvine-based Biogennix , LLC an osteobiologics company specializing in bone graft products for fusion procedures, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an expanded indication for its Agilon Moldable and Morpheus Moldable bone grafting products.

Key Points: 
  • Irvine-based Biogennix , LLC an osteobiologics company specializing in bone graft products for fusion procedures, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an expanded indication for its Agilon Moldable and Morpheus Moldable bone grafting products.
  • Agilon Moldable is unique among moldable synthetic bone grafts, as it contains both collagen with an organic polymer carrier and Biogennix’s proprietary TrelCor granules.
  • "Receiving expanded indications for our flagship Agilon Moldable and Morpheus products is exciting news," said Chris MacDuff, Biogennix’s CEO.
  • Based on enthusiastic feedback from over 75,000 successful cases to date, we anticipate increased market adoption this year for both Agilon and Morpheus moldable products."

From Pioneers to Leaders: Thought Technology Ltd Celebrates its 50th Anniversary at AAPB Conference

Retrieved on: 
Mittwoch, Mai 8, 2024
Education, Tech, Hospital, Certification, Health, Research, ISO, Mental health, Neuro, GSR, Multimedia, CE, Nursing

MONTREAL, May 8, 2024 /PRNewswire-PRWeb/ -- Thought Technology Ltd., a well-established name in the biofeedback equipment sector, is delighted to announce its 50th anniversary. Since its inception, the company has been at the forefront of innovation, providing cutting-edge solutions for biofeedback practitioners worldwide.

Key Points: 
  • The device helps people achieve self-regulation, as a means of keeping stress levels under control.
  • There are more than 450,000 units used worldwide, in thousands of hospitals for numerous health and stress management programs.
  • Asked about reaching this milestone, Thought Technology founder Dr. Hal Myers commented, "It's hard to believe we've been at this for five decades.
  • Thought Technology sponsors a number of workshops, taught by world authorities in their fields, to teach clinical skills and the effective use of biofeedback instrumentation.

Hudson Mind Launches Two-Step Nervous System Treatment to Relieve Anxiety

Retrieved on: 
Dienstag, Mai 7, 2024
Brain, Digestion, Sleep, SGB, Syndrome, Transcranial magnetic stimulation, Research, Heart rate, Parasympathetic nervous system, Nervous system, Pressure, Autonomic nervous system, Sympathetic nervous system, Irritability, Neuro, Hydrodissection, Anxiety, Vagus nerve, Medical imaging

NEW YORK, May 7, 2024 /PRNewswire/ -- Hudson Mind, an interventional mental health clinic in New York City, launched their specialized Neuro Reset treatment, which drastically reduces symptoms of chronic anxiety.

Key Points: 
  • NEW YORK, May 7, 2024 /PRNewswire/ -- Hudson Mind, an interventional mental health clinic in New York City, launched their specialized Neuro Reset treatment, which drastically reduces symptoms of chronic anxiety.
  • Having administered thousands of SGBs, Hudson founder and Chief Medical Officer Dr. Jonathann Kuo developed the Neuro Reset as a means of boosting support for the total nervous system.
  • "To overcome the ongoing cycle of stress that modern life perpetuates, we have to support the total nervous system.
  • Neuro Reset joins a range of clinically-proven interventions at Hudson Mind, including IV ketamine therapy and Transcranial Magnetic Stimulation.

Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Retrieved on: 
Donnerstag, April 18, 2024
American Academy, Mass, Hospital, Stabilizer, White matter, PET, EDSS, Human, Patient, MFIS, Fatigue, DSM-IV codes, Harvard Medical School, Biomarker, Annual general meeting, Associate, Microsoft Access, Neuro, PIRA, Medical imaging

The presentation includes new, encouraging quantitative imaging data from foralumab’s intermediate- size patient population Expanded Access Program.

Key Points: 
  • The presentation includes new, encouraging quantitative imaging data from foralumab’s intermediate- size patient population Expanded Access Program.
  • Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences, commented, “Tiziana is taking a leadership role in focusing on this subset of progressive MS where there are no effective treatments.
  • The study is designed to be open-label and part of the Expanded-Access Program evaluating foralumab in na-SPMS patients that is currently underway.
  • This trial ( NCT06292923 ) is important because if the potential to slow disease progression is demonstrated this would align with early treatment intervention.

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024

Retrieved on: 
Mittwoch, Mai 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Doctor of Philosophy, PFS, Paranal Observatory, Table, License, Summit, Investment, ELCC, Progression-free survival, Research, Intraparenchymal hemorrhage, Immunotherapy, Trial of the century, Webcast, Cohort, Forecasting, PD-1, NGS, TKI, Patient, GRAIL, Brain, SMMT, Neoplasm, EGFR, VEGF, GAAP, Royal institute, Neuro, Lung cancer, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024.
  • In January 2024, followed by a presentation at ELCC 2024 in March 2024, Akeso announced updates from its Phase II AK112-201 trial data.
  • Also at ELCC 2024, Summit and Akeso highlighted promising ivonescimab Phase II data in NSCLC patients with brain metastases.
  • Operating cash outflow for the three months ended March 31, 2024 and 2023 was $30.1 million and $13.1 million, respectively.